top of page

MPNE 2023 

28th- 30th April 2023

Hotel Bloom, Rue Royale- Koningstraat 250, 1210 Brussels, Belgium

Thursday, 27th April

arrival participants for the workshop on Friday morning. 

 

Conference pre-program PCM4EU@MPNE2023

Friday, 28th April 

9.00- 12.00 

Precision Medicine and DRUP- like clinical trials 

 

Separate program and application

Friday

MPNE 2023

prografinal 

Friday, 28th April

SPECIAL SESSION

 

13.00- 14.30

Melanoma in Children, Adolescents and Young Adults- MELCAYA 

Melanoma in children and young patients is hard to diagnose, still lacks treatment options and outcomes too often depend on the patients' living place. Melanom Romania recently joined the MELCAYA EU project as a project partner to precisely work on these issues. MELCAYA builds knowledge on genetic and environmental triggers, how to ensure accurate diagnoses, non-invasive early detection and AI, innovative therapies, and most importantly, how all these could reach patients living in different countries. Melanom Romania's role in MELCAYA includes ensuring connection to the wider European Melanoma community, so if you want to be involved, please let Violeta know!

Welcome to the session and MPNE2023!

Violeta Astratinei, MELCAYA project partner AMeR- Melanoma Romania and MPNE

Bettina Ryll, MPNE

Short introduction to the MELCAYA project

Susana Puig, MELCAYA project coordinator

 

Keynote lecture: Melanoma Risks-  Familial Melanoma and Genetic Predisposition 

Susana Puig, MELCAYA project coordinator, Clinic Barcelona University Hospital

Who is more likely to get melanoma? Melanoma is linked to both environmental and genetic factors. The role of melanoma susceptibility genes is known in adult patients but still under debate in children and adolescent melanoma. Understanding the risk of melanoma helps to prevent and detect melanoma as early as possible.

 

Challenges in Melanoma Diagnosis and a Second Opinion Platform

Daniela Massi, MELCAYA partner, University of Florence 

Why is melanoma sometimes difficult to diagnose, and what makes melanoma in children and adolescents even more challenging? Effective interaction between histopathologists across Europe via digital platforms could improve diagnostic accuracy. Daniela will present general challenges in melanoma diagnostics, the platform for a second opinion, and how patients could benefit.

Healthcare Strategies and Implementation

Laura Sampietro-Colom, MELCAYA partner, Clinic Barcelona University Hospital

 

The work of Laura and her team is to develop tools and guidance for Health Authorities to support the decision-making process on early diagnostics and prevention of melanoma in children. This will include a Health Technology Assessment (HTA) framework for assessing innovative technologies targeting melanoma in children, including ethical and social issues.

 

Why is this important for patients? Health Technology Assessment is how new early diagnosis tools, therapies, or other healthcare interventions can reach patients, so the adoption of innovation highly depends on how good are the HTA frameworks in every European country.

Q&A and discussion: making a difference in CAYA

 

14.00- 15.00

Welcome coffee and registration

 

15.00- 15.55

Conference opening MPNE 2023

Bettina Ryll 

45' MPNE QuickStart

We know that many join us for the first time. MPNE QuickStarts give an introduction to Melanoma as a cancer, the therapies in use and the different Melanoma stages. 

Melanoma in a nutshell

Bettina Ryll 

 

Know your Stage! 

Fredrik Östman and Ian James 

16.00- 17.30

Update Stage 4 Melanoma

A large proportion of MPNE2023 participants are Melanoma patients with Stage 4 Melanoma (55% to be precise). For this reason, we will start with an update on what is currently available as treatment options for Stage 4 Melanoma. While the outlook for Stage 4 patients has improved, treatments still don't work for every patients- which is why the second presentation will be about recent research into response to immune therapy.

Know your Drugs! Understanding Melanoma Therapies 

Bettina Ryll, MPNE

Treatment options for Stage 4 Melanoma 

James Larkin, Royal Marsden London, UK confirmed 

Who responds to LAG3/PD1 inhibition? 

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

Jani Huuhtanen, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland, confirmed

Discussion 

Setting up the advocacy maker space 

 

18.00

The MPNE advocacy maker space 

Time for something new! Community feed-back from the last meetings was that people wanted an Advocacy QuickStart to get up to speed on useful advocacy tools for their work and more time to learn from each other's experiences. 

Advocacy is about change and about building something new, so experimenting and learning are important-  things that did NOT work often have important insights about places of resistance in a system. A toolbox of 'thinking tools' and methods is therefore helpful to move faster- which is why we borrow the maker space concept. 

  • Turn your experience from advocacy work into a learning experience for your colleagues: what do you want them to be aware of to make them succeed? This is an opportunity to be creative- you can obviously make a poster but think about how you can let others experience and test what you've learned. ​

  • Test some tools our community has developed over the years: check the quality of patient information with the V2A2 tool, negotiate a research partnership with our research partnership canvas, help us with building an MPNE impact assessment tool, learn how to draft a patient engagement strategy, contribute to the patient pathway and describe the real impact Melanoma had on your life via the person I worry about and more! 

 

18.30

Advocacy Speed dating with Ian James- in parallel to the maker space 

For those of you who are already getting worried- our advocacy speed dating is the most fast & fun way to get to talk Melanoma advocacy to a large number of people in a very short amount of time. 

Coming for the first time? You'll have met the Melanoma advocate 'dinos' by the end of the session! 

Been here many times before? You will know who is new, have heard some new perspectives and know whom to help!

 

20.00 Buffet dinner at the conference venue

Melcaya-Logo-600x130-transparent.png
Saturday

Saturday, 29th April  

8.00- 8.45 breakfast

 

9.00- 9.45 

Novel developments in drug development 

Bettina Ryll 

While the outcomes in metastatic cutaneous Melanoma have dramatically improved over the last decade, we still lose too many of our community, in particular those with Rare Melanomas. Better research- more relevant, faster- and a more effective integration of research findings into clinical care are therefore important if we want to improve outcomes in Melanoma.

This session will look at efforts to optimise early drug development and the DRUP-like Clinical Trials that are an interesting phenomenon of academically initiated precision medicine trials that provide options for patients whom all lines of treatment have failed.  

Session

Optimising Early Drug Development- UK initiative 

Chris McCabe, Professor of Health Economics, Queen's University Belfast, Ireland, confirmed 

DRUP-like Clinical Trials- how do we get more and better options for more patients? Integrating research into clinical care 

Kjetil Tasken, Director of Institute of Cancer Research at Oslo University Hospital, Norway, confirmed 

Discussion 

9.45- 10.30 

A European Health Data Space that works for patients- because if it doesn't work for patients, it will work for no one.

Gilly Spurrier and Bettina Ryll

In the current discussions around the EHDS and the 2dary use of data, every party has very clear ideas about the value that health data will provide to them. Apart from the convenient 'data altruism' narrative, very little attention is paid to patients- those who first have to consent to their data being used in the first place.

Our community takes a realistic rather than idealistic-naive position: we believe that patients, just as every other stakeholder group, have valid expectations with regards to the value that the usage of their data has to deliver and Gilly will share what that would look like from her perspective. With the individual holding the last control over their data, the control in the system is maximally distributed, protecting the community. Invidual consent thereby becomes the lynch pin around which the entire EHDS revolves- and patient engagement a critical enabler- Teo will share some of her work around the topic, please also read her blog. And last but not least, no system will be fail-safe- patients and societies therefore need the technological and governance solutions to ensure that misuse should it happen will effectively be punished- Philippe will share some of the work of The Human Colossus Foundation on the topic. 

10' Introduction: GILLYWEED- data that works for patients

Gilly Spurrier 

The EHDEN- European Health Data and Evidence project

Nigel Hughes, EHDEN, Belgium, cancelled  

10' People Have the Power: Patient empowerment in the European Health Data Space proposal 

Teodora Lalova-Spinks, Doctoral Researcher at KU Leuven, confirmed 

Read Teo's recent blog on the same topic 

10' Trust by design- technical and governance solutions to manage risks inherent to data sharing

Philippe Page, The Human Colossus Foundation, confirmed 

15' Discussion 

10.30- 11.00 Coffee break

 

11.00- 12.00

Early access to new therapies- Early Access/ Compassionate Use Programs

Fredrik Östman and Bettina Ryll 

Background and motivation 

Early Access- also called Compassionate Use- programs are an important way to access new therapies for Melanoma patients in the dangerous access gap between the end of a confirmatory clinical trial and reimbursement. 

While the evaluation and approval of cancer drugs is coordinated at European level, EAP is not- every country has their own version of it. 

This creates considerable delays and inequity in access to therapies- something we have experienced in the past. 

 

  • Why EAPs are important for us in Melanoma

  • What the current situation in Europe looks like

  • Experiences with the set-up of EAPs in different countries

Session

​​

10' A brief introduction to Compassionate Usage and Early Access

Bettina Ryll, MPNE 

 

15' The Tebentafusp Early Access Program in the UK

Jo Gumbs, OcuMel UK, confirmed 

15' The Dutch Drug Access Protocol, DAP 

Hans Gelderblom, Leiden, confirmed 

20' Discussion with 

Francesco Pignatti, EMA 

all

Further reading

Questions and answers on the compassionate use of medicines in the European Union

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform

The DRUG Access Protocol: access inequality and European harmonisation

 

Overview of Early Access programs in Europe

 

12.15- 13.45 Lunch

 

14.00- 14.45

Treating Melanoma early 

This session is the continuation of a (dinner) conversation that started at ESMO 2021: where are we going with Melanoma treatments? Since the approval of the first new Melanoma drug in 2011, the treatment- and the prognosis- of Melanoma has changed considerably. Today, patients with advanced Melanoma have expectations to survive and want quality, not just quantity of life. With therapies moving earlier and earlier- most recently, into Stage 2, the question of whom to treat how and for how long becomes even more pressing.

Stage 2/3 Melanoma 

Minke Lucas, NKI, Amsterdam, confirmed 

Panel discussion

Minke Lucas with Gilly Spurrier and Violeta Astratinei

  • Survival in Melanoma has improved dramatically, BUT we still loose half of our patients 

  • changing risk/ benefit trade-offs

  • Treating early. What do you mean, it's on me to decide what to do next?!

14.45- 15.30 

Science session: What makes a Melanoma a Melanoma? Triggers and transitions from normal melanocytes to nevus to melanoma 

Maria Pajunen and Bettina Ryll

Heather Etchevers

Research team leader, INSERM (French National Institutes of Health) and MELCAYA consortium member, confirmed

Des Tobin

Director, The UCD Charles Institute of Dermatology, Dublin, Ireland at University College Dublin; confirmed

15.30- 16.00 Coffee

16.00- 17.00

A N1che: Early Melanoma and the iToBoS project 

Ian James and Bettina Ryll

This session's focus is on Early Melanoma, Early Detection and provides an introduction to the iToBoS project. iTOBOS is an EU project funded under the previous program, Horizon2020, and MPNE is project partner. Please also note the linked Early Melanoma sessions on Friday! 

15' Introduction- A patient (advocate)'s perspective on Early Melanoma 

Ian James, MPNE

15' A whole body scanner for the early detection of Melanoma

Rafael Garcia, iTobos; confirmed 

15' Melanoma, Art and AI - Generative Adversarial Network for Personalized Art Therapy in Melanoma Disease Management

Lennart Jütte, Hannover Centre for Optical Technologies, iToBoS; confirmed 

Discussion 

all

17.00- 18.30

HANDS-ON session: How to read a scientific paper

Bettina Ryll, Marianne Bosman and Denise Serré  


In MPNE and all its forums, all statements to scientific findings need to be referenced to its source- is this a scientific publication? A communication? A personal opinion?  

Learn how to read the publication of a clinical study- in parallel groups, we will be reading essential Melanoma studies- the classic ones, plus some of the most interesting recent publications. We use a tool that was originally developed for the ESMO MCBS to structure and analyse the results. 

 

Material and tools provided but please bring your laptop/ tablet.

 

20.00 Conference Dinner

 

Formal dinner attire

In honour of a tradition started by Dick Plomp and in memory of our colleagues we lost 

Roald Nystad

 

Dick and Roald initiated the tradition of formal dinner attire at the conference dinner

a few years ago. During COVID, we have lost several colleagues who have made

important contributions to the Melanoma community.

We will continue a tradition that one of them started in their memory. 

Dinner speech Rob White 

WhatsApp Image 2023-04-20 at 03.59.41.jpeg
Sunday

Sunday, 30th April  

please check out before the session starts

8.30- 9.30 breakfast

 

9.30- 10.00

10' Quality of Life, long-term side effects of new therapies and what MPNE should do about it 

Gilly Spurrier and Bettina Ryll 

15'+ 5' A new EORTC Melanoma QoL module 

Mees Egeler, Ph.D student Psycho-Oncology at Antoni van Leeuwenhoek, NL 

Immune Safety Avatars/ Accelerant- the imSAVAR project

Speaker to be determined- cancelled 

30' Panel- Life is more than survival

Fredrik Östman, Luc Vautmans, Lucy Davis and all 

Further reading

Not Melanoma but read-worthy reflections on long-term toxicity 

10.00- 11.30

ADVOCACY TOOLS: from Theory of Change to Impact

We in MPNE support single individuals and will continue to do so. However, there is only so far this will go- not everyone finds us and our abilities to make a real difference are often limited. Another important part of patient advocacy is therefore to change the system to protect everyone in it- patient advocacy is a particular form of change management. 

In this session, we are therefore testing how to adapt a Theory of Change tool developed by The Grassroots Collective to the different pillars of effective prevention, early detection, treatment and survivorship and see how the different initiatives we are all engaged in contribute to our overall vision of ZERO MELANOMA .

 

This session is part of our work for iToBoS to develop methodology how patient advocates can evaluate the impact of their work. 

 

group work including coffee break 

11.30- 12.30

Advocacy horizons

Many issues encountered by Melanoma patients are not specific to Melanoma. In this session, three advocates will present relevant initiatives that are loosely building on the first session on quality of life and lifel being more than survival: the importance of already capturing QoL during clinical trials, the importance of work- retention during cancer but also re-integration after cancer and the importance of bringing high quality cancer care covering the full spectrum to all patients. 

15'+ 5' EuroACT

Mercè Cases Escuté, Patvocates, confirmed

European Atlas on Clinical Trials in Cancer and Hematology or EuroACT is a research project initiated by WECAN and the European Hematology Community. The project aims to understand the clinical trial landscape in the European region, based on data extracted from all relevant European clinical trial registers. Data from the past five years will unveil differences where clinical trials have been run in European countries and will describe how and which patient-reported outcomes (PROs) and quality-of-life (QoL) instruments have been used in clinical trials.

15'+ 5' Cancer and work

Isabelle Lebroque, oPUCE, NL,  confirmed

Unfortunately, cancer is not only a medical problem but also affects all other domains of life, including work. Isabelle founded oPUCE to facilitate work retention and return to work during and after cancer and has built an inspiring organisation. 

15'+ 5' Equality in Beating Cancer 

Olga Valcina, OncoAlliance and Melanoma association, Latvia, confirmed

In March 2022, OncoAlliance organised a European meeting on Equality in Beating Cancer that ended with with the  Riga Open Letter on Equality in Beating Cancer

12.30- 13.15

Us in MPNE  

We are working on a way to capture our advocacy activities and interests between us- so that everyone gets an idea what colleagues are working and after a weekend of lots of information, new people and new ideas- a way to find like-minded people for inspiration, someone to learn from and someone to teach for the next months. Watch the space!

13.15

Conference summary and conclusions

Bettina Ryll

13:30 Lunch and departure 

Location

Hotel Bloom

Brussels

attendance

Follow

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page